Jiangxi Institute of Biological Products Inc
Company Profile
Business description
Jiangxi Institute of Biological Products Inc is principally engaged in the business of research and development, and production and sale of human tetanus antitoxin. It operates as the provider and exporter of Human TAT in China and an antiserum platform company. Its products include biological products containing immunoglobulins or immunoglobulin F(ab')2 fragments, which are used in medical applications such as tetanus, snakebite envenoming, and rabies treatment. The majority of the company's revenue is derived from the sale of Human Tetanus Antitoxin in the Chinese mainland.
Contact
No. 198 Huoju Avenue
Jinggangshan Economic and Technological Development Zone
Jiangxi Province
Ji’an
CHNT: +86 75533209772
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
33
Stocks News & Analysis
stocks
Wide moat share expects luck to turn
stocks
ASX share’s growth story intact despite supply constraints
stocks
ASX healthcare giant rallies despite a fall in profits
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,269.70 | 13.70 | -0.15% |
| CAC 40 | 8,484.43 | 31.34 | 0.37% |
| DAX 40 | 26,136.56 | 153.52 | 0.59% |
| Dow JONES (US) | 53,277.01 | 517.80 | 0.98% |
| FTSE 100 | 10,816.56 | 68.40 | 0.64% |
| HKSE | 26,009.46 | 310.97 | 1.21% |
| NASDAQ | 26,180.46 | 113.29 | 0.43% |
| Nikkei 225 | 66,016.36 | 200.43 | -0.30% |
| NZX 50 Index | 13,972.66 | 52.84 | 0.38% |
| S&P 500 | 7,674.37 | 33.21 | 0.43% |
| S&P/ASX 200 | 9,058.90 | 6.90 | -0.08% |
| SSE Composite Index | 3,905.20 | 1.48 | 0.04% |